Cliff Asness's BIO Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 31,971 shares of Bio-Rad Laboratories, Inc. (BIO) worth $8.73 M, representing 0.01% of the portfolio. First purchased in 2015-Q2, this long-term strategic position has been held for 42 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in BIO, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2019, adding 137,361 shares. Largest reduction occurred in Q2 2022, reducing 221,115 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Bio-Rad Laboratories (BIO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Bio-Rad Laboratories (BIO) Trades by Cliff Asness
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2015 | +16,482 | New Buy | 16,482 | $150.59 |
| Q3 2015 | +59,808 | Add 362.87% | 76,290 | $134.32 |
| Q4 2015 | +19,983 | Add 26.19% | 96,273 | $138.66 |
| Q1 2016 | +34,772 | Add 36.12% | 131,045 | $136.72 |
| Q2 2016 | -41,618 | Reduce 31.76% | 89,427 | $143.02 |
| Q3 2016 | -30,578 | Reduce 34.19% | 58,849 | $163.81 |
| Q4 2016 | -6,866 | Reduce 11.67% | 51,983 | $182.27 |
| Q1 2017 | +7,144 | Add 13.74% | 59,127 | $199.33 |
| Q2 2017 | -393 | Reduce 0.66% | 58,734 | $226.31 |
| Q3 2017 | -28,008 | Reduce 47.69% | 30,726 | $222.22 |
| Q4 2017 | +17,924 | Add 58.33% | 48,650 | $238.66 |
| Q1 2018 | -13,978 | Reduce 28.73% | 34,672 | $250.09 |
| Q2 2018 | +25,702 | Add 74.13% | 60,374 | $288.55 |
| Q3 2018 | +98,634 | Add 163.37% | 159,008 | $312.99 |
| Q4 2018 | +12,112 | Add 7.62% | 171,120 | $232.22 |
| Q1 2019 | +76,072 | Add 44.46% | 247,192 | $305.68 |
| Q2 2019 | -87,486 | Reduce 35.39% | 159,706 | $306.10 |
| Q3 2019 | +22,775 | Add 14.26% | 182,481 | $332.74 |
| Q4 2019 | +137,361 | Add 75.27% | 319,842 | $370.03 |
| Q1 2020 | +66,260 | Add 20.72% | 386,102 | $348.68 |
| Q2 2020 | -32,314 | Reduce 8.37% | 353,788 | $437.96 |
| Q3 2020 | -118,431 | Reduce 33.48% | 235,357 | $515.46 |
| Q4 2020 | -84,474 | Reduce 35.89% | 150,883 | $572.01 |
| Q1 2021 | +2,536 | Add 1.68% | 153,419 | $570.01 |
| Q2 2021 | +13,306 | Add 8.67% | 166,725 | $644.29 |
| Q3 2021 | +11,753 | Add 7.05% | 178,478 | $745.95 |
| Q4 2021 | +50,425 | Add 28.25% | 228,903 | $752.62 |
| Q1 2022 | +61,695 | Add 26.95% | 290,598 | $563.23 |
| Q2 2022 | -221,115 | Reduce 76.09% | 69,483 | $490.65 |
| Q3 2022 | -29,690 | Reduce 42.73% | 39,793 | $417.13 |
| Q4 2022 | -5,800 | Reduce 14.58% | 33,993 | $416.91 |
| Q1 2023 | -13,514 | Reduce 39.76% | 20,479 | $474.88 |
| Q2 2023 | -14,133 | Reduce 69.01% | 6,346 | $379.12 |
| Q3 2023 | +21,651 | Add 341.18% | 27,997 | $357.99 |
| Q4 2023 | +8,459 | Add 30.21% | 36,456 | $322.89 |
| Q1 2024 | +9,634 | Add 26.43% | 46,090 | $345.77 |
| Q2 2024 | +1,864 | Add 4.04% | 47,954 | $273.00 |
| Q3 2024 | -17,427 | Reduce 36.34% | 30,527 | $330.90 |
| Q4 2024 | -1,147 | Reduce 3.76% | 29,380 | $328.51 |
| Q1 2025 | -10,801 | Reduce 36.76% | 18,579 | $238.51 |
| Q2 2025 | +9,610 | Add 51.73% | 28,189 | $241.32 |
| Q3 2025 | +3,782 | Add 13.42% | 31,971 | $272.99 |
Cliff Asness's Bio-Rad Laboratories Investment FAQs
Cliff Asness first purchased Bio-Rad Laboratories, Inc. (BIO) in Q2 2015, acquiring 16,482 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Bio-Rad Laboratories, Inc. (BIO) for 42 quarters since Q2 2015. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's largest addition to Bio-Rad Laboratories, Inc. (BIO) was in Q4 2019, adding 319,842 shares worth $118.35 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 31,971 shares of Bio-Rad Laboratories, Inc. (BIO), valued at approximately $8.73 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Bio-Rad Laboratories, Inc. (BIO) represents approximately 0.01% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's peak holding in Bio-Rad Laboratories, Inc. (BIO) was 386,102 shares, as reported at the end of Q1 2020. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.